perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316963;](https://doi.org/10.1101/2024.11.08.24316963) this version posted November 8, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

# <sup>17</sup> **Abstract**

18 Since the 2022-2023 season in Portugal, a high-dose quadrivalent influenza vaccine is freely 19 available for individuals living in long-term care facilities (LTCF). In 2024-2025, vaccination was 20 extended to community-dwelling individuals aged ≥85 years. Given the scarcity of reported high-21 dose influenza vaccine effectiveness (IVE) estimates for this population, this study aims to 22 estimate the high-dose relative and absolute IVE.

23 A retrospective cohort study using data from electronic health records databases (EHR) will be 24 implemented, using two cohorts, one of individuals vaccinated with influenza vaccine (to 25 estimate relative IVE) and another of individuals eligible for the high-dose quadrivalent influenza 26 vaccine (to estimate absolute IVE). We will consider two subgroups for both cohorts: individuals 27 living in LTCF and community-dwelling individuals aged ≥85. We will use a fixed cohort approach, 28 defining the eligible population by age at the vaccination campaign(s) start and living status. The 29 outcomes are based on the primary cause of hospital admission. The reference population 30 database will be defined by linking EHR on vaccination, comorbidities, and hospitalisations using 31 a unique identifier through a deterministic data linkage procedure, and influenza vaccination 32 status will be assessed retrospectively. We will use Cox proportional hazards regression models 33 to estimate the hazard ratio (HR), considering as event the first hospitalisation due to influenza-34 like-illness and as exposure the vaccination status. IVE will be estimated as one minus the 35 confounder-adjusted HR of vaccinated with the high-dose quadrivalent influenza vaccine vs 36 vaccinated with standard dose (to estimate relative IVE) or unvaccinated (to estimate absolute 37 IVE).

38 While challenges such as EHR constraints and potential reporting bias pose limitations, using 39 routinely collected data has successfully estimated COVID-19 VE and enables precise monitoring

- 40 of VE with higher representativeness. The results of this study will inform the Health Ministry on
- 41 the future influenza vaccine programme in Portugal.

# <sup>42</sup> **Keywords**

- 43 Quadrivalent Influenza Vaccine, Vaccine Effectiveness, Electronic Health Records, Portugal, Long-
- 44 Term Care Facilities
- 45

# <sup>46</sup> **Background**

47 In Portugal, as in most European countries, influenza seasonal immunisation is recommended 48 annually to high risk individuals, which include, among others, elderly individuals (age 49 stratification varies across seasons, i.e., aged ≥60 or aged ≥65 years) and those who reside in 50 long-term care facilities (LTCF)(1).

51 Adults aged 65 or more are more prone to lower respiratory tract infections, including 52 pneumonia, bronchitis, and tracheobronchitis, due to specific factors, such as genetic 53 polymorphisms, chronic immunocompromised conditions, age and correspondent age-related 54 comorbidities, that may compromise the individual capacity to produce an adequate immune 55 response(2,3). These infections are associated with considerable morbidity and can lead to 56 hospitalisation, especially in frail older adults, such as those residing in LTCF (4). There is a 57 potentially different risk of exposure in older community-dwelling individuals due to the greater 58 number of contacts. Additionally, LTCFs significantly contribute to the variability in exposure to 59 the disease between individuals, resulting in greater individual susceptibility to severe outcomes 60 (4,5).

61 Vaccination is widely considered the most effective intervention against influenza and its 62 associated complications (5). However, influenza vaccination strategies might target individuals 63 who, although at high risk of influenza complications, may have impaired capacity for developing 64 effective vaccine-induced immunity. Given the specificities of individuals in LTCF, the effect of 65 influenza vaccination in this population needs further investigation (2,5). A high-dose 66 quadrivalent influenza vaccine was developed to provide greater protection and better prevent 67 influenza-related complications than the standard dose influenza vaccine.

68 This high-dose quadrivalent vaccine presented higher efficacy in a randomised clinical trial versus 69 a standard-dose influenza vaccine for preventing laboratory-confirmed influenza illness in adults 70 aged 65 or more (3). Systematic reviews and meta-analyses, which included randomised and 71 observational studies, assessed the effectiveness of high-dose inactivated influenza vaccines 72 versus standard-dose influenza vaccines against influenza-related outcomes in 65 or more years 73 old individuals (6,7). The results support the evidence on the effectiveness of high-dose 74 inactivated influenza vaccines compared to standard-dose influenza vaccines in preventing 75 severe influenza outcomes in 65 or more years old individuals, with additional support from 76 observational data (7). Regarding severity-related outcomes, the high-dose quadrivalent 77 influenza vaccine was more effective than the standard-dose influenza vaccine in preventing 78 influenza-related hospitalisations, with a relative influenza vaccine effectiveness (rIVE) of 11.2% 79 (7.4%-14.8%) for all seasons. Despite the important evidence of the effectiveness of the influenza 80 vaccine (IVE) of the high-dose inactivated influenza vaccines for individuals aged 65 or older, only 81 three studies in nursing homes were included (6). Review studies indicated a need for further 82 real-world population-based studies of high-dose influenza vaccines. Hence, it remains necessary 83 to assess the clinical effectiveness of this vaccine in older adults living in LTCF (7–9).

84 In Portugal, since the 2022-2023 season (1,10), the high-dose quadrivalent influenza vaccine is 85 available exclusively for individuals aged 65 or more living in LTCF, free of charge. In the 2023-24 86 season, the high-dose influenza vaccine became available to community-dwelling individuals 87 aged 65 or more in community pharmacies, with co-payment if the patient presents a 88 prescription (11).

89 Given the scarcity of reported high-dose IVE estimates for this population and the Portuguese 90 strategy of vaccinating institutionalised individuals aged 65 or more, it is crucial to evaluate the 91 vaccine's effect on preventing severe outcomes in this age group of the Portuguese population. 92 Thus, the objective of this study is to estimate the rIVE of the high-dose quadrivalent influenza 93 vaccine against hospital admission due to influenza-like-illness in individuals vaccinated with any 94 influenza vaccine and the absolute IVE of the high-dose quadrivalent influenza vaccine against 95 hospital admission due to influenza-like-illness in individuals eligible for the high-dose 96 quadrivalent vaccine, using data routinely collected in electronic health records (EHR) in 97 mainland Portugal.

98

# <sup>99</sup> **Methods**

## 100 **Study design and population**

101 A retrospective cohort study using data collected routinely in EHR databases will be 102 implemented. For the estimation of rIVE, only vaccinated individuals will be included, either with 103 the high-dose or the standard influenza vaccine. For the estimation of absolute IVE, individuals 104 eligible for the high-dose influenza vaccine during the study period will be included. For both



116

117 We will use a fixed cohort approach, defining the eligible population by their age at the start of 118 the vaccination campaign(s) and living status. Table 1 describes the connection between the 119 cohorts and the objectives.

- 120
- 121 **Table 1.** Summary of the study design with the different cohorts, objectives and exposed and 122 unexposed groups





123 IVE – influenza vaccine effectiveness; LTCF – long-term care facilities

124

# 125 **Inclusion and exclusion criteria**

126 The study population includes all registered individuals without contraindications for influenza 127 vaccination residents in mainland Portugal. Only vaccinated individuals with the high-dose 128 quadrivalent or standard influenza vaccine living in LTCF or community-dwelling individuals aged 129 85 or older will be included to estimate rIVE. Whereas, to estimate absolute IVE, only eligible 130 individuals for the high-dose influenza vaccine living in LTCF or community-dwelling individuals 131 aged 85 or older will be included.

132 We will exclude individuals with inconsistent or missing data on vaccination (e.g. any vaccination

133 date unknown and any vaccine brand unknown), individuals who received any vaccine brand not

134 approved by the European Medicines Agency (EMA), and individuals vaccinated before the study 135 started.

# 136 **Study setting and period**

- 137 To estimate rIVE, the study population will include individuals vaccinated with the high-dose or 138 standard influenza vaccine in mainland Portugal between the 2022/2023 and 2024/2025 139 seasons. When applicable, we will analyse each season (2022/2023, 2023/2024, 2024/2025) 140 individually, starting after the implementation of each influenza vaccination campaign and 141 ending nine months thereafter.
- 142 To estimate absolute IVE, the study population will include individuals for whom the high-dose 143 influenza vaccine has been recommended in mainland Portugal for the 2024/2025 season. The 144 study period will start after the implementation of the influenza vaccination campaign period 145 and end nine months thereafter.

## 146 **Vaccination status**

147 To estimate rIVE, the vaccination status will be assessed retrospectively, and the time since 148 vaccination will be estimated. The exposure of interest will be to receive the high-dose 149 quadrivalent influenza vaccine, and the comparison group will be composed of those who 150 received the standard-dose influenza vaccine.

151 To estimate absolute IVE, the vaccination status will be assessed as a time-changing variable 152 according to the following classification:

- 153 o Unvaccinated: person-time of individuals without any quadrivalent influenza vaccine in 154 the season.
- 155 o Vaccinated: person-time of individuals who received a high-dose quadrivalent influenza 156 vaccine dose during the study period. The completion status is achieved 14 days after 157 administration of the dose.

## 158 **Time since vaccination**

159 If the sample size allows it, the time since completion of the high-dose influenza vaccine will be 160 analysed as a secondary objective. For the rIVE estimation, time since vaccination will be 161 considered a confounder to add to the model. For the absolute IVE estimation, time since 162 vaccination will be calculated at each time point and classified into the following categories:

- 163 From time 14 days to ≤89 days after time 0 (i.e., <13 weeks, approximately 3 months);
- 164 90 to 179 days after time 0 (i.e., ≥13 weeks and <26 weeks, approximately 3 to 6 months);
- 165 180 to 272 days (i.e., ≥26 weeks and <39 weeks, approximately 6 to 9 months).

#### 166 **Outcome**

167 The outcomes of interest are defined based on the primary cause of admission to a hospital, 168 coded according to ICD-10: J11 (Influenza with pneumonia), J12 (Viral pneumonia) and J18 169 (Pneumonia of unknown aetiology).

170 As a secondary outcome, we will also analyse cardiorespiratory hospitalisations as a primary 171 cause of admission, with a secondary diagnosis of pneumonia (flu, viral or unknown aetiology). 172 Each of these outcomes will be analysed separately. The outcome date will correspond to the 173 hospitalisation date. Details on the ICD-10 codes are available in Supplementary Table S1.

### 174 **Stratification variables**

175 If possible, and when applicable, rIVE will be estimated for each seasonal campaign.

## 176 **Potential confounding variables for adjustment**

177 A set of variables will be used to account for confounding bias. Sociodemographic variables, such 178 as sex, age, health administrative region, and the European Deprivation Index, will be used as 179 potential confounding factors. We will also consider the vaccination against COVID-19 in the 180 previous season to account for health-seeking behaviours. The presence of chronic conditions, 181 such as diabetes, asthma, or other chronic respiratory diseases, cancer, chronic renal disease, 182 hypertension or other chronic cardiovascular disease, obesity, chronic hepatic disease, 183 neuromuscular disease, and immunodeficiency, will also be included as potential confounding 184 factors.

#### 185 **Data sources**

186 The study will use routinely collected data from various population health registries. Each 187 database will contain a unique identifier for each individual to allow data linkage between 188 databases.

189 The National Health Service User (NHSU) dataset is the reference population database and 190 includes individual records of the target study population. For this study, we will only consider 191 individuals who had contact with the NHSU healthcare system three years before the start of the 192 study period.

193 Vaccination registry or vaccination record databases with individual data, including influenza and

194 vaccine brand dates, will be provided by the National Vaccination Registry – VACINAS.

195 Regarding the outcome, the National Hospital Discharges Registry will be used to assess 196 hospitalisation information. We will also use data on mortality, which will be extracted from the 197 National Death Registry, with the respective date of death.

## 198 **Construction of the cohort**

#### 199 **Identification of individuals and characteristics at baseline**

200 The reference population database will be linked with the electronic databases on vaccination, 201 comorbidities and/or health-seeking behaviours, hospitalisations and other vital registries, using 202 the unique identifiers through a deterministic data linkage procedure (no random component in 203 the linkage procedure). Individuals will enter the study in their corresponding vaccination status 204 group based on the data available in the vaccination registry.

205 Variables to be measured at baseline include age, sex, health administrative region, 206 comorbidities, and other socioeconomic or health-seeking behaviour variables that will be used 207 to adjust IVE estimates to stratify or account for confounding.

#### 208 **Time-changing characteristics (to estimate absolute IVE)**

209 Vaccination status and time since vaccination will be assessed, and individuals will be classified 210 into the same or updated vaccination status daily, generating a new record in the dataset for 211 each new assessment. Person-time exposure between 0 and 13 days after vaccination will be 212 excluded from the analysis.

### 213 **Identification of outcomes during follow-up**

- 214 Information for identifying outcomes and the dates when they occurred will be obtained by data
- 215 linkage between the cohort built previously and the databases containing information on the
- 216 respective outcomes. Outcome classification for each individual will be assessed from the start
- 217 of the vaccination campaign.

#### 218 **Censoring events**

- 219 All individuals will be followed from the start of the vaccination campaign until:
- 220 o Hospitalisation date (corresponding to the event date);
- 221  $\circ$  At the end of the study (nine months after the start of the vaccination campaign);
- 222 o On the date of death (any cause).

#### 223 **Analysis plan**

#### 224 **Description of the sample selection**

- 225 The total number of individuals fulfilling the inclusion criteria at the study baseline will be
- 226 calculated for each cohort. The number and proportion of individuals excluded after applying
- 227 each selection criteria will be recorded.

#### 228 **Description of the study population**

- 229 The number of persons, total person-time of follow-up, and the number of events by vaccination
- 230 status will be calculated. Distribution of the number of persons and total person-time of follow-
- 231 up will be described by baseline variables in each vaccination status group considered in the

232 study. To estimate the total number of persons, we will consider the vaccination status group at 233 the end of each person-time follow-up (to estimate absolute IVE).

234 The proportion of the missing data will be used to determine if each specific variable can be 235 included in the model and how (e.g., missing could eventually be included in the model as a 236 category). Imputation to address missingness is not planned as a means for increasing data 237 quality.

## 238 **Estimation of the vaccine effectiveness**

239 A complete case analysis will be performed considering all variables in the final model to estimate 240 adjusted-confounding IVE.

241 We will use Cox proportional hazards regression models to estimate the hazard ratio (HR), 242 considering the event the first hospitalisation due to influenza-like-illness and as exposure the 243 vaccination status. The crude HR of vaccinated with the high-dose influenza vaccine vs vaccinated 244 with the standard dose (rIVE) or unvaccinated (absolute IVE) will be estimated for each outcome 245 of interest during the study period, without adjusting for other factors or covariates.

246 We will consider two sets of confounding factors. First, we will estimate partially adjusted HR, 247 adjusting by age, sex and country region. Age will be modelled using a restricted cubic spline, 248 with knots specified according to Harrell (12). Second, a fully adjusted HR estimate will be 249 produced by adjusting variables related to socioeconomic condition, comorbidities and health-250 seeking behaviour. IVE will be estimated as one minus the confounder-adjusted HR of vaccinated 251 vs vaccinated with the standard dose (rIVE) or unvaccinated (absolute IVE) for each outcome of 252 interest.

#### 253 IVE =  $(1 - aHR) * 100$

254 To estimate relative IVE, the time since vaccination will be modelled using a restricted cubic 255 spline, with knots specified at zero and 15 days and then at the  $40<sup>th</sup>$  and  $90<sup>th</sup>$  percentile. To 256 estimate absolute IVE for the time since vaccination (secondary objective), IVE will be estimated 257 by comparing the hazard rate of the outcome in individuals vaccinated with the high-dose 258 influenza vaccine for each class of the time since vaccination - 14 to 89 days, 90 to 179 days and 259 180 to 272 days (exposed group), in comparison with the outcome hazard rate in unvaccinated 260 individuals (reference group).

#### 261 **Propensity score matching**

262 Individual characteristics might influence vaccination status, leading to systematic differences 263 between those vaccinated with different vaccines and those vaccinated (rIVE) and unvaccinated 264 (absolute IVE). Propensity score matching is a statistical technique used to reduce selection bias 265 in observational studies by creating a matched set of treated (vaccinated with high-dose 266 influenza vaccine) and untreated (vaccinated – rIVE and unvaccinated – absolute IVE) individuals 267 with similar propensity scores. The first option will be matching without replacement, 1-to-1. 268 However, considering the coverage vaccination, this ratio might need to be reviewed.

269 Several assumptions should be met to ensure that conditioning on the propensity score will lead 270 to unbiased estimates of average treatment effects. The first one is that there should not be 271 unmeasured confounders, i.e. the variables affecting vaccination status and hospitalisation due 272 to influenza-like-illness should have been measured. The second relates to positivity, each 273 individual should have a non-zero probability of getting the high-dose influenza vaccine. 274 Additionally, the propensity score model should be correctly defined, and there should not be 275 any interference between individuals, i.e., an individual vaccinated with the high-dose influenza

276 vaccine will not affect the hospitalisation of another individual. This final assumption has 277 implications in estimating absolute IVE studies due to herd immunity since vaccinated individuals 278 could indirectly protect unvaccinated individuals, leading to IVE underestimation. To account for 279 potential violations of this assumption, we will consider statistical methods that account for 280 clustering, which could be the geographical region of residence.

281 The propensity score will be estimated using logistic regression, where the vaccination status will 282 be the outcome, and the baseline individual characteristics will be used to adjust. Then, the 283 vaccinated with high-dose influenza vaccine and vaccinated (rIVE) or unvaccinated (absolute IVE) 284 individuals with similar propensity scores will be matched, using nearest neighbour matching, 285 and compared to ensure the balance of covariates. Once the balanced dataset is obtained, the 286 Cox proportional hazards regression model will be used, with the adjustments mentioned in the 287 section above to adjust for residual confounding (13).

## 288 **Ethics**

289 This protocol was submitted to the National Institute of Health Doutor Ricardo Jorge Ethics 290 Committee (INSA-EC) in 2024 July 19<sup>th</sup> and approved on July 30<sup>th</sup>.

## 291 **Discussion**

292 This article outlines the conceptual framework and methodological approach to estimate high-293 dose quadrivalent IVE using EHR in the community and LTCF. We intend to estimate the risk of 294 hospitalisation reduction by comparing two vaccination strategies (High-dose quadrivalent 295 influenza vaccine and standard-dose influenza vaccine – rIVE), and comparing vaccinated with 296 unvaccinated individuals (absolute IVE). To date, retrospective cohort studies regarding high-

297 dose quadrivalent IVE in reducing influenza-related hospitalisation of individuals aged 65 or older 298 have been conducted using specific populations, such as United States veterans or health 299 insurance beneficiaries (10–13). To the best of our knowledge, studies on the effect of high-dose 300 influenza vaccines in LTCF remain limited to immunogenicity studies.

301 Given the population under study, LTCF and community-dwelling individuals (≥85 years), the 302 potential low vaccine coverage in the eligible population, and the absence of specific studies 303 designed to collect data in LTCF settings, we decided to use routinely collected data in electronic 304 health registries to estimate the high-dose quadrivalent IVE. This approach has already been used 305 successfully to estimate COVID-19 VE (14), and allows VE monitoring with good precision and 306 high representativeness(15–18).

307 Despite its strengths, this study also has some limitations. We plan to use EHR, which does not 308 aim to collect data for research purposes. Thus, this could lead to misclassification bias regarding 309 vaccine status, outcomes, and confounding variables. For this reason, we might be unable to 310 control for residual confounding since many relevant variables are not monitored or available in 311 registries, and one should be aware that estimates can vary in the presence of confounding. 312 Additionally, unvaccinated individuals will be the reference group when estimating absolute IVE. 313 However, these individuals might differ from the vaccinated individuals due to their clinical 314 profile or possible misclassification bias. Thus, we will use propensity score matching to account 315 for this, assigning a probability of being vaccinated to each individual based on covariates. 316 Considering that we will use EHRs, we might also be unable to correctly identify all individuals 317 living in LTCF, as the report might vary geographically and temporally. Additionally, identifying 318 these individuals might be associated with a differential bias, assuming that vaccinated

319 individuals might be more likely to be reported as living in LTCF than unvaccinated. This situation 320 is less likely to be problematic when estimating relative and absolute IVE in the community.

321 Another limitation is the potential outcome misclassification. In VE studies, it is extremely 322 important to have sensible outcome definitions as the vaccines are designed to protect against 323 influenza and related complications and studies use laboratory-confirmed outcomes. Using 324 specific influenza ICD codes to identify severe influenza could underestimate severe influenza as 325 the diagnosis is highly dependent on the testing strategy and, thus, on the codification attributed 326 at discharge. On the other hand, including a broader range of ICD codes in the outcome definition 327 could also underestimate IVE by including non-influenza-related outcomes. To balance this, we 328 intend to use ICD codes that have been used for a long time in influenza surveillance and are 329 highly sensitive. Finally, we intend to use discharge codes, as they are the final primary diagnosis 330 of the hospitalisation. However, there are delays in hospital discharge and the codification of the 331 hospitalisation event. In order to minimise this, the retrospective study will only use end-of-332 season data.

333 In conclusion, the study aims to produce estimates of high-dose IVE in the population eligible for 334 the high-dose vaccine and contribute to the overall knowledge of the potential added protection 335 provided by this vaccine. Given the vaccination strategy implemented in this population and the 336 national effort in acquiring and implementing vaccination strategies, evaluating the effect of such 337 public health intervention is crucial. The results will also inform decision-makers in future IVE. 338 Additional future studies should include, not only relative indicators, but also quantitative 339 measures of the vaccination strategy's impact on the population (19).

340

# <sup>341</sup> **Authors' contributions**

342 PS and AM conceptualised and designed the study. AM, PS and VG wrote the first draft of the 343 protocol. APR, VG, JAS provided technical inputs. All authors revised and approved the final 344 version.

## <sup>345</sup> **References**

- 346 1. Direção-Geral de Saúde. Campanha de Vacinação Sazonal contra a Gripe: Outono-Inverno 347 2024-2025. 2024;
- 348 2. Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative 349 effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US 350 nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir 351 Med [Internet]. 2017;5(9):738–46. Available from: http://dx.doi.org/10.1016/S2213- 352 2600(17)30235-7
- 353 3. Diaco M, Chang LJ, Seet B, Robertson CA, Chit A, Mercer M, et al. Introductory paper: High-354 dose influenza vaccine. Vaccine [Internet]. 2021;39:A1–5. Available from: 355 https://doi.org/10.1016/j.vaccine.2020.09.005
- 356 4. Furman CD, Rayner A V., Tobin EP. Pneumonia in older residents of long-term care 357 facilities. Am Fam Physician. 2004;70(8):1495–500.
- 358 5. Gozalo PL, Pop-Vicas A, Feng Z, Gravenstein S, Mor V. Effect of influenza on functional 359 decline. J Am Geriatr Soc. 2012;60(7):1260–7.
- 360 6. Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older 361 adults by age and seasonal characteristics: Systematic review and meta-analysis update.

362 Vaccine X [Internet]. 2023;14(June 2022):100327. Available from: 363 https://doi.org/10.1016/j.jvacx.2023.100327

- 364 7. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of 365 high-dose influenza vaccine in older adults by circulating strain and antigenic match: An 366 updated systematic review and meta-analysis. Vaccine [Internet]. 2021;39:A24–35. 367 Available from: https://doi.org/10.1016/j.vaccine.2020.09.004
- 368 8. Robison SG, Thomas AR. Assessing the effectiveness of high-dose influenza vaccine in 369 preventing hospitalization among seniors, and observations on the limitations of 370 effectiveness study design. Vaccine [Internet]. 2018;36(45):6683–7. Available from: 371 https://doi.org/10.1016/j.vaccine.2018.09.050
- 372 9. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of 373 Influenza Vaccines among the United States Elderly, 2018-2019. J Infect Dis. 374 2020;222(2):278–87.
- 375 10. DGS Direção Geral da Saúde, Direção Geral de Saúde, Machado A. Campanha de 376 Vacinação Sazonal contra a Gripe: Outono-Inverno 2022-2023. 2023;(January):1–9. 377 Available from: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-378 circulares-normativas/norma-n-0072022-de-02092022-pdf.aspx
- 379 11. Direção Geral de Saúde. Norma de Orientação Clínica nº 006/2023: Campanha de 380 Vacinação Sazonal contra a Gripe: Outono- Inverno 2023-2024. 2023;1–12.
- 381 12. FE. H. Regression modeling strategies: with applications to linear models, logistic 382 regression, and survival analysis. New York: Springer; 2001. 568 p.
- 383 13. Austin PC. An introduction to propensity score methods for reducing the effects of
	- 19

384 confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.

- 385 14. Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative 386 complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-387 CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case– 388 case study based on electronic health records. Influenza Other Respi Viruses. 389 2023;17(3):1–10.
- 390 15. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of
- 391 COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using
- 392 electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March
- 393 2022. Eurosurveillance [Internet]. 2022;27(30). Available from: 394 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.30.2200551
- 395 16. Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID-396 19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic 397 health registries in ≥65 years old population in six European countries, October 2021 to 398 November 2022. Influenza Other Respi Viruses. 2023;17(11):1–10.
- 399 17. Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, et al. Relative 400 vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results 401 from a VEBIS network, Europe, October 2021 to July 2023. Eurosurveillance. 2024;29(1):1–
- 402 8.
- 403 18. Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. 404 Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 405 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.

406 Influenza Other Respi Viruses. 2024;18(4):1–6.

- 407 19. Young-Xu Y, Snider JT, Mahmud SM, Russo EM, van Aalst R, Thommes EW, et al. High-dose
- 408 influenza vaccination and mortality among predominantly male, white, senior veterans,
- 409 United States, 2012/13 to 2014/15. Eurosurveillance. 2020;25(19):1–10.



Exposure - vaccinated with high-dose quadrivalent influenza vaccine

# Figure 1